BR112012001031A8 - Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência - Google Patents

Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência

Info

Publication number
BR112012001031A8
BR112012001031A8 BR112012001031A BR112012001031A BR112012001031A8 BR 112012001031 A8 BR112012001031 A8 BR 112012001031A8 BR 112012001031 A BR112012001031 A BR 112012001031A BR 112012001031 A BR112012001031 A BR 112012001031A BR 112012001031 A8 BR112012001031 A8 BR 112012001031A8
Authority
BR
Brazil
Prior art keywords
substituted
treatment
spiro
sleep disorders
compounds suitable
Prior art date
Application number
BR112012001031A
Other languages
English (en)
Other versions
BR112012001031A2 (pt
Inventor
Luigi Piero Stasi
Lucio Rovati
Original Assignee
Rottapharm Spa
Rottapharm Biotech Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa, Rottapharm Biotech Srl filed Critical Rottapharm Spa
Publication of BR112012001031A2 publication Critical patent/BR112012001031A2/pt
Publication of BR112012001031A8 publication Critical patent/BR112012001031A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

COMPOSTOS ESPIRO AMINO ADEQUADOS PARA O TRATAMENTO DE INTER ALTA DISTÚRBIOS DO SONO E TOXICODEPENDÊNCIA. A invenção refere-se a um composto espiro -amino de fórmula (VI) em que m 1 ou 2 ou 3,n é 1 ou 2, R é selecionado de um anel aromático de 5 ou 6 membros e um anel heteroaromático de 5 ou 6 membros compreendendo de 1 a 3 heteroaromático selecionados de S, O e N, tal anel sendo substituído com um ou dois substituídos selecionados do grupo consistindo em (C1-C3) alquil, halogênio, C5 ) cicloalquiloxi, ( C1 -C3 ) alquilcarbonil, fenil opcionalmente substituído com um mais átomos de halogênio, um heterociclo de 5 ou 6 membros compreendendo pelo menos um átomo de nitrogênio; F é um substituído Q ou COQ, onde é selecionado onde Q é selecionado do grupo consistindo em fenil piridil, pirimidil, quinolil ,isoquilonil, quinoxalil, benzofuraril ,imidazotriazolil,sendo Q opcionalmente substituído com um ou mais substituintes selecionados do grupo consistindo em (C1-C3) alquil,halogênio, trifluormetil,carbamido,metilcarbamido carboxi, metilcarboxi ou um sal farmaceuticamente aceitável deste.
BR112012001031A 2009-07-15 2010-07-15 Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência BR112012001031A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425285A EP2275421A1 (en) 2009-07-15 2009-07-15 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
PCT/EP2010/060206 WO2011006960A1 (en) 2009-07-15 2010-07-15 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction

Publications (2)

Publication Number Publication Date
BR112012001031A2 BR112012001031A2 (pt) 2016-11-22
BR112012001031A8 true BR112012001031A8 (pt) 2017-09-19

Family

ID=41820711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001031A BR112012001031A8 (pt) 2009-07-15 2010-07-15 Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência

Country Status (12)

Country Link
US (1) US8859608B2 (pt)
EP (2) EP2275421A1 (pt)
JP (1) JP5814917B2 (pt)
KR (1) KR101736424B1 (pt)
CN (1) CN102471314B (pt)
AU (1) AU2010272548B2 (pt)
BR (1) BR112012001031A8 (pt)
CA (1) CA2768329C (pt)
ES (1) ES2537658T3 (pt)
MX (1) MX2012000577A (pt)
RU (1) RU2562609C2 (pt)
WO (1) WO2011006960A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484674A1 (en) * 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
ES2559513T3 (es) 2011-07-04 2016-02-12 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas del receptor EP4
ITMI20112329A1 (it) * 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
EP2811997B1 (en) 2012-02-07 2018-04-11 Eolas Therapeutics Inc. Substituted prolines/piperidines as orexin receptor antagonists
ITMI20120322A1 (it) 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
CN104610129B (zh) * 2015-01-08 2017-07-18 爱斯特（成都）生物制药有限公司 一种手性2‑取代基‑4‑哌啶酮‑1‑羧酸叔丁酯的合成方法
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
AU2018326734B2 (en) * 2017-09-01 2023-08-17 Chronos Therapeutics Limited Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists
JP2023540344A (ja) * 2020-09-03 2023-09-22 センテッサ ファーマシューティカルズ （オレキシア） リミテッド 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
PL176993B1 (pl) * 1992-12-11 1999-08-31 Merck & Co Inc Nowe związki spiropiperydynowe oraz sposób ich wytwarzania
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1286141B1 (it) 1996-07-02 1998-07-07 Rotta Research Lab Derivati diammidici dell'acido antranilico ad attivita' antigastrinica procedimento per la loro preparazione e loro uso farmaceutico.
CN100448874C (zh) 2001-05-05 2009-01-07 史密斯克莱·比奇曼公司 N-芳酰基环胺
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US20060040937A1 (en) 2002-09-18 2006-02-23 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
EP1922071A2 (en) * 2005-08-26 2008-05-21 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists
WO2008038251A2 (en) * 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
US20080287479A1 (en) 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
AR064561A1 (es) * 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
JP2010526869A (ja) * 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
NZ580887A (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
TW200904799A (en) 2007-07-27 2009-02-01 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
CA2713184A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives

Also Published As

Publication number Publication date
JP2012532916A (ja) 2012-12-20
KR20120038487A (ko) 2012-04-23
EP2454252B1 (en) 2015-03-04
AU2010272548A1 (en) 2012-02-23
ES2537658T3 (es) 2015-06-10
RU2562609C2 (ru) 2015-09-10
US8859608B2 (en) 2014-10-14
CN102471314B (zh) 2015-05-13
JP5814917B2 (ja) 2015-11-17
KR101736424B1 (ko) 2017-05-29
RU2012105284A (ru) 2013-08-20
EP2454252A1 (en) 2012-05-23
WO2011006960A1 (en) 2011-01-20
EP2275421A1 (en) 2011-01-19
AU2010272548B2 (en) 2013-08-22
BR112012001031A2 (pt) 2016-11-22
CN102471314A (zh) 2012-05-23
MX2012000577A (es) 2012-05-08
CA2768329A1 (en) 2011-01-20
US20120115882A1 (en) 2012-05-10
CA2768329C (en) 2017-03-07

Similar Documents

Publication Publication Date Title
BR112012001031A8 (pt) Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência
HRP20180483T1 (hr) Spoj kinolona
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
EA201290260A1 (ru) Бензимидазол-имидазольные производные
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
JP2014525420A5 (pt)
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
JP2016536363A5 (pt)
MX2016006564A (es) Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
IN2014DN03063A (pt)
BRPI0615111B8 (pt) composto, composição farmacêutica, e, uso do composto
ECSP088812A (es) Derivados de dihidropirazolopirimidinona
NZ627586A (en) Pyridone derivatives
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
JP2014502988A5 (pt)
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
RU2018105614A (ru) Производное 1,3,5-триазина и способ его применения
ATE480239T1 (de) Angiogeneseinhibitoren
AR082827A1 (es) Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ROTTAPHARM BIOTECH S.R.L. (IT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.